Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589303 · ClinicalTrials.gov registry record · Phase 3
AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
A Phase 3 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT00589303: Clinical Trial Phase 3 study, sponsored by Mayo Clinic.
NCT00589303 is a Phase 3 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00589303, a Phase 3 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
Interventions
- DRUG FDA approved rate and rhythm control drugs
- DEVICE AV Node ablation and device implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00589303
The ClinicalTrials.gov registry entry for NCT00589303 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FDA approved rate and rhythm control drugs is the first listed.
NCT00589303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00589303 about?
NCT00589303 is a clinical study titled "AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study". The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
What is the current status of trial NCT00589303?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2007-12. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00589303?
The interventions under investigation include: FDA approved rate and rhythm control drugs (DRUG), AV Node ablation and device implant (DEVICE).
Who is sponsoring clinical trial NCT00589303?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.